ClinicalTrials.gg
CompletedNCT00772863Tax-OverUpdated Oct 29, 2009

Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer

A Phase 2 interventional study of docetaxel and cisplatin in Ovarian Neoplasms, sponsored by Sanofi. Completed at 1 site in Turkey. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-10-29.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing docetaxel in Ovarian Neoplasms — none open to participants now, none under way, none of them phase 3. Docetaxel · Ovarian Neoplasms.

Enrollment
13th of 32
37 · median 34
Started
2003
with 7 others
Phase 2
23 of 38
none open now
Registered
32nd of 38
by date
Lead sponsor
3 of 38
Sanofi

Among the 38 studies testing docetaxel in Ovarian Neoplasms, this one is the 13th largest by enrollment of the 32 interventional ones that give a count, is one of 8 that started in 2003, is one of 23 in phase 2, and was the 32nd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 38 studies testing docetaxel in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 38 studies testing docetaxel in Ovarian Neoplasms as a file.
02

Study summary

The purpose of this study is to assess the efficacy and the safety of the treatment.

03

Conditions studied

  • Ovarian Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically/ confirmed, optimally debulked stage III-IV epithelial ovarian cancer excluding clear cell histology.
  • Performance Status is 0-2
  • No prior chemotherapy for this ,
  • Acceptable hematological profile (as defined by a leukocyte count ≥ 3000/mm3, a count ≥ 100.000mm3 and ≥ 9g/100mL), and adequate renal function (as defined by serum creatinine ≤ 1.5mg/dl or by formulation ≥ 60 mL/min), and hepatic function (as defined by ≤ 1.5 x maximum normal value even with hepatic ; transaminases (, AST) ≤ 1.5 x maximum normal value; alkaline phosphatase ≤ 2.5 x maximum normal value, except in case of a bone metastasis)

Exclusion criteria

Exclusion Criteria:

  • Concomitant use of another anti-cancer therapy
  • Unstable medical condition that makes the patient unable to take part in a clinical study (congestive heart failure, serious arrythmia, uncontrolled diabetes mellitus), history of myocardial infarction within last 3 months, massive pleural, peritoneal or pericardial effusion; or presence of serious uncontrolled infection.
  • Presence of other tumours different from basal cell carcinoma of the skin.
  • Pregnancy or breastfeeding. In women of and in men, an adequate method must be used
  • Social or psychological condition that render the patient inadequate for the follow-up of the study
  • for any of the study drugs (e.g. history of to any of the ingredients of the study drugs)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Interventions

  • Drugdocetaxel and cisplatin

    Drug pages: Docetaxel · Cisplatin

    4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks

06

What researchers measure

Primary outcomes

  1. Efficacy by response rate according to RECIST criteria and safety

    Time frame: After the 2nd cycle, 4th cycle and 8th cycle and at the follow up period

Secondary outcomes

  1. Time to disease progression or relapse

    Time frame: Until progression througout the study

  2. Survival time

    Time frame: Througout the study

  3. Quality of life based on the questionnaire EORTC QLQ-C30 filled by the patients

    Time frame: Prior to entry, after completion of treatment and at the first follow-up visit

07

Study locations

1 site
  • Sanofi aventis administrative office
    Istanbul, Turkey
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003 and a primary completion of Jun 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2008
First posted
Oct 15, 2008
Start
Sep 2003
Primary completionActual
Jun 2008
Last update
Oct 29, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00772863
Lead sponsor
Sanofi
First posted
Oct 15, 2008
Start date
Sep 2003
Primary completion
Jun 2008
Last update
Oct 29, 2009

Study contacts

Edibe Taylan, MD
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Cisplatin

Start the discussion